Description
NT-0796 is an inhibitor of the NOD-like receptor protein 3 (NLRP3) inflammasome and a prodrug form of NDT-19795.1 It selectively inhibits NLRP3 over NLR family CARD domain-containing protein 4 (NLRC4) at 3 nM, as well as a panel of 121 other receptors at 10 µM, but does inhibit the serotonin (5-HT) receptor subtype 5-HT2B by 90% at 10 µM. NT-0796 inhibits LPS- and ATP-induced IL-1β release in isolated human peripheral blood mononuclear cells (PBMCs) and whole blood (IC50s = 0.32 and 6.8 nM, respectively), however, it does not affect LPS-induced TNF-α or IL-6 release in isolated human PBMCs (IC50s = >2 µM for both), indicating NLRP3 selectivity. It decreases body weight, food intake, and plasma levels of total cholesterol, HDL, and proprotein convertase subtilisin kexin type 9 (PCSK9) in a model of high-fat diet-induced obesity using transgenic mice expressing human carboxylesterase-1 (CES1), the enzyme that converts NT-0796 to NDT-19795, when administered at a dose of 100 mg/kg three times per day.2WARNING This product is not for human or veterinary use.
References
[1] DAVID HARRISON. Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders.[J]. Journal of Medicinal Chemistry, 2023: 14897-14911. DOI:
10.1021/acs.jmedchem.3c01398[2] PETER THORNTON. Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796.[J]. Journal of Pharmacology and Experimental Therapeutics, 2024: 813-826. DOI:
10.1124/jpet.123.002013
